Bryan Garnier is a full-service growth-focused independent investment bank headquartered in Paris, with offices across Europe and North America.▪ Co-led the firm’s healthcare investment banking practice with global coverage and responsibility.▪ Established the firm’s North America corporate finance business through the merger of Brocair Partners with Bryan Garnier in 2019 and co-manage the firm’s North American business.▪ Originated landmark transactions including the first institutional private placement for a high-profile, award winning digital health business, and the sale of a rapidly-growing digital pathology platform for 9x forward revenue.▪ Managed client relationships and oversaw projects, while developing and maintaining relationships with hundreds of strategic buyers and investors worldwide.

Founder & Managing Partner of this healthcare-dedicated corporate finance advisory group. Brocair advised on mergers & acquisitions, financings, and strategic advisory services for companies in life sciences, medical technology, biopharmaceuticals, healthcare informatics, consumer health, and healthcare services.▪ Engaged on dozens of sell-side and buy-side M&A and financing transactions with clients that include family-owned, private equity-owned, and publicly-traded businesses.Selected notable transactions:- Advised Coltene on its acquisition of Liechtenstein-based dental products company KENDA- Advised Novasep on its $39m divestiture of life science business TangenX to Repligen- Advised Briggs Healthcare on its acquisition of healthcare software maker SimpleLTC Systems- Advised UDG Healthcare on its $144m acquisition of medical communications business KnowledgePoint360- Advised Biomain, a Swedish dental products business, on its sale to Heraeus Kulzer- Advised publicly-listed CDMO, Synthetech, on its sale to W.R. Grace- Advised a U.S.-based wound healing center business on its sale to Candescent Partners- Advised BSE-listed Plethico Pharmaceuticals on its $82m acquisition of Nasdaq-listed consumer health business, Natrol▪ Developed thousands of relationships with healthcare executives and investors across all sectors within the healthcare industry.▪ Created an international network of clients, contacts, and business partners across North America, Europe, Latin America, and Asia, and completed many cross-border transactions.▪ Built and managed client relationships with hundreds of large corporate organizations and private equity funds.▪ Designed and executed on deep research efforts into a range of healthcare industry subsectors, resulting in frequent focused buy-side engagements and published reports that were widely utilized by industry professionals and investors.

Burnham Securities is a full service, generalist boutique investment bank that was the successor entity to Drexel Burnham Lambert.▪ Led the execution team on M&A transactions, financings, and fairness opinions in a variety of industries; the majority of transactions were healthcare-related.▪ Developed and wrote information memorandums, client presentations, new business pitches, fairness opinions, and worked regularly with client executives and investors.

Marco Polo is a trade execution network and clearinghouse for institutional investors focused on emerging markets. It also operated an emerging markets-focused investment banking group, founded by an IB team from Lehman Brothers.▪ Drafted the business architecture for their trade processing and communication links with equity brokers overseas. Fifth employee to join the company.▪ Assisted senior bankers with M&A and financing transactions across a variety of industries and emerging economies.

CEO of this start-up online retail brokerage focused on the European Union and headquartered in Dublin, Ireland.

The Risk Management group within Lehman Brothers was responsible for monitoring all aspects of the firm’s risk, including market exposure and customer credit exposure.▪ Risk management responsibilities, embedded within the equity derivative trading floor. Responsible for quarterly reporting of the firm’s exposure to market risk and customer risk, assessed through stress testing the firm’s positions.▪ Developed the tools that the firm used to perform these tests, utilizing data from multiple systems in multiple global regions.